SHIRE PLC (NASDAQ:SHPG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

As Shire plc (“Shire”) previously announced on Form 8-K filed August 21, 2017, Jeff Poulton will be stepping down as Chief Financial Officer (“CFO”) of Shire. His last day of employment will be December 31, 2017. As previously announced on Form 8-K filed November 20, 2017, Thomas Dittrich is expected to assume the role of CFO in early 2018. John Miller (49), Shire’s Senior Vice President of Finance, will serve as interim CFO with effect from January 1, 2018 until Mr. Dittrich commences his employment with Shire.

Mr. Miller joined Shire in 2004 and, in addition to his current role in which he has served since March 2015, has served in a number of positions including, in the past five years, as Vice President of Finance, Neuroscience from June 2010 to March 2015.

In connection with his new role, Mr. Miller has entered into a new letter agreement governing the terms of his appointment as interim CFO, to which, while serving as interim CFO his annual base salary will increase to $765,000.

About SHIRE PLC (NASDAQ:SHPG)

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.